San Fegan Biotech

Sanfegan Biotech is a clinical-stage biopharmaceutical company based in Beijing, China, dedicated to developing innovative therapies for chronic viral hepatitis. The company was co-founded by Dr. Wenhui Li, the renowned scientist who identified the Sodium taurocholate cotransporting polypeptide (NTCP) as the functional receptor for HBV and HDV entry. Sanfegan's lead candidate, SFG785, is a potent small molecule NTCP inhibitor designed to block viral entry and prevent the reinfection of hepatocytes. Currently in Phase 2 clinical trials, the company's pipeline aims to provide a functional cure for patients suffering from chronic Hepatitis B and Hepatitis D. Sanfegan leverages its deep expertise in molecular virology to address significant unmet needs in liver disease treatment.